Raphael Pharmaceutical (RAPH) Notes Payables (2020 - 2026)

Raphael Pharmaceutical has disclosed Notes Payables across 7 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Notes Payables rose 132.27% year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (up 132.27% YoY), while the FY2025 annual figure was $946000.0, up 314.91% from the prior year.
• Notes Payables came in at $1.3 million for Q2 2026 at Raphael Pharmaceutical, up from $946000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $1.3 million in Q2 2026 to a low of $1000.0 in Q1 2022.
• Average Notes Payables over 5 years is $302533.3, with a median of $40000.0 recorded in 2023.
• Year-over-year, Notes Payables slumped 86.36% in 2022 and jumped 2069.23% in 2025.
• Over 5 years, Notes Payables stood at $3000.0 in 2022, then surged by 1166.67% to $38000.0 in 2023, then jumped by 500.0% to $228000.0 in 2024, then jumped by 314.91% to $946000.0 in 2025, then jumped by 38.48% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $1.3 million in Q2 2026, $946000.0 in Q4 2025, and $755000.0 in Q3 2025.